It's top ten time again. This week, among our most popular stories was the worrying news that, accoridng to research conducted at Queen Mary University of London, up to 64% of antiobiotics made and sold in India are unapproved.
Elsewhere, the M&A engine keeps chugging as Allergan snapped up Elastagen and its skincare molecule for $95 million. But the most popular news this week was the blow dealt to Novartis as it learned its generic version to GSK's Advair will be delayed to market.
